New research has found that semaglutide, a popular medication used to treat diabetes and obesity, may help protect kidney function in people who have excess weight and cardiovascular disease (CVD).
The findings, which were presented at the 61st ERA Congress Friday, suggest that receiving a weekly injection of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may help prevent complications like chronic kidney disease and end-stage renal disease that often occur alongside obesity.
Health experts say the results are encouraging as they indicate that semaglutide may be an effective therapeutic option for treating comorbidities, and ultimately, improving people’s quality of life.
